These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37905858)

  • 1. Empagliflozin reduces brain pathology in Alzheimer's disease and type 2 diabetes.
    Hierro-Bujalance C; Garcia-Alloza M
    Neural Regen Res; 2024 Jun; 19(6):1189-1190. PubMed ID: 37905858
    [No Abstract]   [Full Text] [Related]  

  • 2. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes.
    Hierro-Bujalance C; Infante-Garcia C; Del Marco A; Herrera M; Carranza-Naval MJ; Suarez J; Alves-Martinez P; Lubian-Lopez S; Garcia-Alloza M
    Alzheimers Res Ther; 2020 Apr; 12(1):40. PubMed ID: 32264944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics.
    Avgerinos KI; Mullins RJ; Vreones M; Mustapic M; Chen Q; Melvin D; Kapogiannis D; Egan JM
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury.
    Wiciński M; Wódkiewicz E; Górski K; Walczak M; Malinowski B
    Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33187206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Subcortical Atrophy and Alzheimer's Pathology on Cognition in Elderly Type 2 Diabetes: The Alzheimer's Disease Neuroimaging Initiative Study.
    Zhang W; Lu J; Qing Z; Zhang X; Zhao H; Bi Y; Zhang B;
    Front Aging Neurosci; 2022; 14():781938. PubMed ID: 35173604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.
    Aronow WS; Shamliyan TA
    Ann Transl Med; 2017 Dec; 5(23):455. PubMed ID: 29285488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
    Mason T; Coelho-Filho OR; Verma S; Chowdhury B; Zuo F; Quan A; Thorpe KE; Bonneau C; Teoh H; Gilbert RE; Leiter LA; Jüni P; Zinman B; Jerosch-Herold M; Mazer CD; Yan AT; Connelly KA
    JACC Cardiovasc Imaging; 2021 Jun; 14(6):1164-1173. PubMed ID: 33454272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhao D; Liu H; Dong P
    J Hum Hypertens; 2019 Apr; 33(4):327-339. PubMed ID: 30443007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes, Alzheimer's disease and apolipoprotein genotype.
    Messier C
    Exp Gerontol; 2003 Sep; 38(9):941-6. PubMed ID: 12954480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.
    James BD; Wilson RS; Boyle PA; Trojanowski JQ; Bennett DA; Schneider JA
    Brain; 2016 Nov; 139(11):2983-2993. PubMed ID: 27694152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, Alzheimer's disease and dementia in the Baltimore Longitudinal Study of Ageing.
    Dolan D; Troncoso J; Resnick SM; Crain BJ; Zonderman AB; O'Brien RJ
    Brain; 2010 Aug; 133(Pt 8):2225-31. PubMed ID: 20647264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stress induced exacerbation of Alzheimer's disease brain pathology is thwarted by co-administration of nanowired cerebrolysin and monoclonal amyloid beta peptide antibodies with serotonin 5-HT6 receptor antagonist SB-399885.
    Sharma HS; Feng L; Muresanu DF; Tian ZR; Lafuente JV; Buzoianu AD; Nozari A; Bryukhovetskiy I; Manzhulo I; Wiklund L; Sharma A
    Int Rev Neurobiol; 2023; 171():3-46. PubMed ID: 37783559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.
    Mesulam MM; Weintraub S; Rogalski EJ; Wieneke C; Geula C; Bigio EH
    Brain; 2014 Apr; 137(Pt 4):1176-92. PubMed ID: 24574501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets.
    Hamzé R; Delangre E; Tolu S; Moreau M; Janel N; Bailbé D; Movassat J
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute neuropathological consequences of short-term mechanical ventilation in wild-type and Alzheimer's disease mice.
    Lahiri S; Regis GC; Koronyo Y; Fuchs DT; Sheyn J; Kim EH; Mastali M; Van Eyk JE; Rajput PS; Lyden PD; Black KL; Ely EW; D Jones H; Koronyo-Hamaoui M
    Crit Care; 2019 Feb; 23(1):63. PubMed ID: 30795776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes.
    Madonna R; Doria V; Minnucci I; Pucci A; Pierdomenico DS; De Caterina R
    J Cell Mol Med; 2020 Nov; 24(21):12331-12340. PubMed ID: 32940423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.